Axicabtagene Ciloleucel
‘Reassuring’ study shows no link between CAR T-cell therapy and secondary cancers
A new retrospective analysis has added to building evidence that suggests chimeric antigen receptor T-cell therapy does not directly cause secondary malignancies.
‘Wake-up call’: Cancer cachexia causes worse outcomes after CAR-T for lymphoma
Historically, Jae H. Park, MD, has not paid much attention to his patients’ weight loss.
Axi-cel exhibits durable benefit in advanced indolent non-Hodgkin lymphoma
SAN DIEGO — Treatment with axicabtagene ciloleucel conferred durable benefit to patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, according to study results presented at ASH Annual Meeting and Exposition.
Serious cardiovascular events rare after CAR T-cell therapy
A meta-analysis of patients who underwent chimeric antigen receptor T-cell therapy for advanced blood cancers showed low prevalence of cardiovascular adverse events.
Axi-cel ‘can be curative’ for large B-cell lymphoma, but nonrelapse mortality a concern
A real-world evaluation of axicabtagene ciloleucel for individuals with relapsed or refractory large B-cell lymphoma showed 5-year OS, PFS and disease-specific survival rates comparable to those observed in clinical trials.
Risk for second primary malignancies no greater with CAR-T than other standard therapies
Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.
Shorter monitoring period after CAR-T may be possible, potentially expanding access
An FDA mandate that requires patients who receive chimeric antigen receptor T-cell therapy to stay within a certain radius of their treatment facility for nearly a month for adverse event monitoring may be overly restrictive.
FDA requires boxed safety warning for all CAR T-cell therapies
The FDA has requested manufacturers of commercially available chimeric antigen receptor T-cell therapies now include a boxed safety warning regarding the risk for secondary T-cell malignancies on prescribing labels.
FDA official says CAR-T ‘incredibly beneficial’ despite secondary malignancy risk
Benefits of chimeric antigen receptor T-cell therapy far outweigh the risks involved, including secondary T-cell malignancies, according to Peter Marks, MD, PhD, director of the FDA’s Center for Biologic Evaluation and Research.
CAR-T vs. bispecifics for lymphoma: Using the evidence to sequence treatments
Curative potential at a longer follow-up, logistics and patient risk and eligibility are all important considerations when sequencing bispecific antibodies and chimeric antigen receptor T-cell therapy for advanced large B-cell lymphoma.